Holen Sie sich die Stockscreener-App
5.395
0.16%
-0.005
Curevac N V Aktie (CVAC) Neueste Nachrichten
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
BioNTech SE Announces Acquisition of CureVac N.V. - TipRanks
Germany: BioNTech to acquire CureVac in all-stock transaction - Investors in Healthcare
BioNTech to Acquire CureVac in Strategic Move - TipRanks
CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances - MarketScreener
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction - Global Legal Chronicle
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise - simplywall.st
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead By Investing.com - Investing.com Nigeria
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of - Bluefield Daily Telegraph
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BioNTech CureVac Acquisition Boosts Cancer Drug Pipeline - Industry Leaders Magazine
CureVac (CVAC) Receives Downgrade and Price Target Reduction fro - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewswire
Jefferies cuts CureVac stock rating to hold on BioNTech acquisition By Investing.com - Investing.com UK
BioNTech: Oddo BHF raises target price - marketscreener.com
BioNTech to buy CureVac in USD 1.25 billion all-stock deal - Medical Dialogues
CureVac Stock: BioNTech's Billion-Dollar Takeover Bid - sharewise
BioNTech (BNTX) to Acquire CureVac in $1.25 Billion All-Stock De - GuruFocus
CureVac (CVAC) Downgraded by Jefferies Analyst After BioNTech Acquisition Agreement | CVAC Stock News - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in P - GuruFocus
BioNTech Announces Strategic Acquisition of CureVac - TipRanks
Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty - BioWorld MedTech
BioNTech to Acquire CureVac in $1.25B Deal - USA Herald
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer (BNTX) - Seeking Alpha
5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal - Law360
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders - MarketScreener
BioNTech to acquire CureVac in $1.25 billion all-stock deal By Investing.com - Investing.com South Africa
BioNTech to Acquire CureVac to Expand mRNA Cancer Therapies - N24.com.tr
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal - BioPharma Dive
Watkins Advises on BioNTech’s US$1.25 Billion Acquisition of CureVac - Latham & Watkins LLP
M&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion Deal - TipRanks
CureVac Stock Soars on BioNTech Buyout - Schaeffer's Investment Research
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
BioNTech Buys CureVac For $1.25 Billion In Stock Deal - Finimize
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday - Benzinga
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments - Investopedia
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead - Investing.com
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals - marketscreener.com
Vaccine developer with Boston HQ acquired for $1.25B - NBC Boston
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year ahead By Investing.com - Investing.com India
Sector Update: Health Care Stocks Lean Lower Premarket Thursday - MarketScreener
BioNTech to Buy CureVac for $1.25 Billion for Cancer Boost - Bloomberg
M&A News: BioNTech Snaps Up CureVac in $1.25B Deal to Supercharge Cancer Pipeline - TipRanks
Germany's BioNTech to buy CureVac to boost cancer research - Yahoo
BioNTech to buy former Boston Covid vaccine rival for $1.25B - The Business Journals
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders - Business Wire
BioNTech, CureVac Agree to All-stock Purchase Deal - MarketScreener
Oracle and CureVac rise premarket; Boeing and GameStop fall By Investing.com - Investing.com UK
BioNTech to Buy CureVac in All-Stock Deal - marketscreener.com
CureVac stock soars about 30% after BioNTech agrees to acquire co - Investing.com Australia
CureVac stock soars about 30% after BioNTech agrees to acquire co By Investing.com - Investing.com South Africa
BioNTech To Acquire CureVac In All-stock Deal With Aggregate Equity Value Of Approx. $1.25 Bln - Nasdaq
BioNTech to Acquire CureVac in All-Stock Deal - marketscreener.com
Biontech Announces Strategic Transaction To Acquire Curevac In Public Exchange Offer - marketscreener.com
Squarepoint Ops LLC Sells 23,122 Shares of CureVac (NASDAQ:CVAC) - Defense World
Two Sigma Investments LP Invests $391,000 in CureVac (NASDAQ:CVAC) - Defense World
1.62%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):